3.8 Article

Subcutaneous Sweet Syndrome Successfully Treated With Ustekinumab in a Patient With Ulcerative Colitis

Journal

ACG CASE REPORTS JOURNAL
Volume 9, Issue 11, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/crj.0000000000000881

Keywords

-

Funding

  1. Chan Zuckerberg Biohub Physician Scientist Scholar Award
  2. NIH NIDDK LRP Award [L30 DK126220]
  3. Doris Duke Phy-sician Scientist Fellowship Award [2021091]

Ask authors/readers for more resources

This study presents the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with ulcerative colitis successfully treated with ustekinumab.
Ustekinumab, an inhibitor of the interleukin-12/23 pathway, received Food and Drug Administration (FDA) approval in 2019 for induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis (UC). Data regarding the efficacy of ustekinumab in the treatment of extraintestinal manifestations of UC are unclear. Sweet syndrome, an acute febrile neutrophilic dermatosis, is a cutaneous manifestation of inflammatory bowel disease that parallels disease activity. In this study, we present the first case of subcutaneous Sweet syndrome with sterile osteomyelitis in a patient with UC successfully treated with ustekinumab.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available